The value of amniopatch in pregnancies associated with spontaneous preterm premature rupture of fetal membranes: a randomized controlled trial

J Matern Fetal Neonatal Med. 2021 Jan;34(2):267-273. doi: 10.1080/14767058.2019.1605348. Epub 2019 May 7.

Abstract

Objective: To evaluate the efficacy and safety of amniopatch in pregnancies associated with spontaneous preterm premature rupture of fetal membranes (PPROM).Methods: A randomized controlled trial that involved 100 women diagnosed with PPROM between 24 and 34 weeks of gestational age. Participants were randomized equally into two groups. Group I in which amniopatch was done in addition to the routine management. Group II was treated with routine management including antibiotics and corticosteroids.Results: Amniopatch was successful in complete sealing of the membrane defect in 6/50 (12%) of women while none the control group have undergone similar sealing (p = .0144, RR = 0.88). Women in the amniopatch group showed a significant increase of AFI compared to controls (12 versus 0, p = .0001, RR = 0.56).Conclusion: The amniopatch procedure is a successful technique that safely enhances sealing of fetal membranes and restore the AFI.Clinical trial registration: NCT03473210SynopsisThe amniopatch procedure is a successful technique that could be done safely to enhance sealing the fetal membranes and restoring the AFI after PPROM.

Keywords: Amniopatch; preterm labor; preterm prelabor rupture of membrane (PPROM).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adrenal Cortex Hormones
  • Extraembryonic Membranes
  • Female
  • Fetal Membranes, Premature Rupture*
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Pregnancy

Substances

  • Adrenal Cortex Hormones